Fig. 1: High-throughput screening for antiviral compounds against PRRSV.
From: High-throughput screening unveils nitazoxanide as a potent PRRSV inhibitor by targeting NMRAL1
a Strategy diagram for GFP expression post-PRRSV infection in cells. Following PRRSV infection, the virus encounters cellular negative-strand PRRSV genome analogs, converting them into positive-strand RNA, subsequently expressing GFP. b Flow cytometry diagram of GFP expression induced in Marc-145-GFP cell line post-PRRSV infection. GFP-expressing cells increased by 25.8% in Marc-145-GFP cells post-PRRSV infection. c Indirect immunofluorescence image of Marc-145-GFP cells post-PRRSV infection. Cells infected with PRRSV expressed GFP in conjunction with PRRSV-N protein within the same cells. d Strategy diagram for implementing HTS. Compounds, GSWW-18 (Multiplicity of Infection, MOI = 1), and Marc-145-GFP cells were co-introduced into 96-well plates. The first column of the plate was for Mock treatment, with the addition of equal concentration Dimethyl sulfoxide (DMSO) and virus, and the last column contained 60 µM Ribavirin. e Raw data from all screening plates. DMSO treatment group (Mock, blue), negative control group (NC, yellow), potential hits (Hit, red), 60 µM Ribavirin positive control group (RBV, orange), compound library (Library, green). Data represent the average of three to five images per well. f Identification of enriched targets for potential antiviral compounds through GSEA. Compounds were ranked according to antiviral activity, and enrichment scores were then ranked, with the top 6 targets shown in the diagram (P < 0.05, false discovery rate (FDR) q < 0.5). P-values were generated using a one-sided hypergeometric test. Each black line in the diagram represents a compound.
